References
Agrahari V, Li G, Agrahali V, Navarro I Perkumas K, Mandal A, et
al.(2017) ‘Pentablock copolymer dexamethasone nanoformulations elevate
MYOC : in vitro liberation , activity and safety in human trabecular
meshwork cells. Nanomed (London) 12: 1911–1926 doi:
10.2217-0140.
Boland MV, Chang DS, Frazier T, Plyler R, Friedman DS (2014) Electronic
monitoring to assess adherence with once-daily glaucoma medications and
risk factors for nonadherence: the automated dosing reminder study.JAMA Ophthalmol 132: 838-844.
Caprioli J, Sears M, Bausher L, Gregory D, Mead A (1984) Forskolin
lowers intraocular pressure by reducing aqueous inflow’,Investigative Ophthalmology and Visual Science , 25: 268–276.
Coleman RA, Woodrooffe AJ, Clark KL, Toris CB, Fan S, Wang J, Woodward
DF (2018) ‘The affinity, intrinsic activity and selectivity of a
structurally novel prostaglandin EP 2 receptor agonist
at human prostanoid receptors’, British Journal of Pharmacology .
doi: 10.1111/bph.14525.
el-Shabrawi Y, Eckhardt M, Berghold A, Faulborn J, Auboeck L, Mangge H,
Ardjomand N (2000) ‘Synthesis pattern of matrix metalloproteinases
(MMPs) and inhibitors (TIMPs) in human explant organ cultures after
treatment with latanoprost and dexamethasone.’, Eye (London,
England) 14: 375–383. doi: 10.1038/eye.2000.92.
Forster C,
Kahles
T,
Kietz
S,
Drenckhahn
D (2007) ‘Dexamethasone induces the expression of metalloproteinase
inhibitor TIMP-1 in the murine cerebral vascular endothelial cell line
cEND.’, The Journal of physiology 580: 937–949. doi:
10.1113/jphysiol.2007.129007.
Fuwa M, Toris CB, Fan S, Taniguchi T, Ichikawa M, Odani-Kawabata Net al. (2018) ‘Effects of a Novel Selective EP2 Receptor Agonist,
Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular
Hypertensive Monkeys’, Journal of Ocular Pharmacology and
Therapeutics 34: 531–537. doi: 10.1089/jop.2017.0146.
Gerritsen ME, Weinstein BI, Gordon GG, Southren AL (1986) ‘Prostaglandin
synthesis and release from cultured human trabecular-meshwork cells and
scleral fibroblasts.’, Experimental eye research .43:1089–1102.
Gregory D, Sears M, Bausher L, Mishima H, Mead A (1981) ‘Intraocular
pressure and aqueous flow are decreased by cholera toxin.’,Investigative ophthalmology & visual science . 20: 371–381.
Hacker, M. C. and Mikos, A. G. (2011) ‘Chapter 33 - Synthetic Polymers’,
in Atala, A. et al. (eds). San Diego: Academic Press, pp. 587–622. doi:
https://doi.org/10.1016/B978-0-12-381422-7.10033-1.
Hermans, E. (2003) ‘Biochemical and pharmacological control of the
multiplicity of coupling at G-protein-coupled receptors.Pharmacology and Therapeutics , 99: 25–44. doi:
10.1016/S0163-7258(03)00051-2. .
Jiang J, Ganesh T, Du Y, Thepchatri P, Rojas A, Lewis I et al. (2010),
Neuroprotection by selective allosteric potentiators of the EP2
prostaglandin receptor. Proc Nat Acad Sci 107: 2307-2312. doi:
10.1073/pnas.1120195109.
Kandola MK,
Sykes
L,
Lee
YS,
Johnson
MR,
Hanyaloglu
AC,
Bennett
PR (2014) ‘EP2 receptor activates dual g protein signaling pathways
that mediate contrasting proinflammatory and relaxatory responses in
term pregnant human myometrium’, Endocrinology , 155: 605–617.
doi: 10.1210/en.2013-1761.
Kennedy CR Zhang Y, Brandon S, Guan Y, Coffee K, Funk CD, et al.(1999) ‘Salt-sensitive hypertension and reduced fertility in mice
lacking the prostaglandin EP2 receptor.’, Nature medicine . United
States, 5(2), pp. 217–220. doi: 10.1038/5583.
Kilkenny C, Browne W. Cuthill IC, Emerson M, Altma DG (2010). Animal
research: reporting in vivo experiments: the ARRIVE guidelines.
British Journal of Pharmacology 160: 1577-1579 doi:
10.4103/0976-500X.72351
Ko, MK, Tan, JCH (2013) ‘Contractile markers distinguish structures of
the mouse aqueous drainage tract’, Molecular Vision 19:
2561–2570. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867161/.
Maqsood U, Ho TN, Palmer K, Eccles FJ, Munavvar M, Wang R, Crossingham
I, Evans DJ (2019) Once daily long-acting beta2-agonists and long-acting
muscarinic antagonists in a combined inhaler versus placebo for chronic
obstructive pulmonary disease. Cochrane Database Syst Rev doi:
10.1002/14651858 CDO12930.
Matrisian LM (1990) ‘Metalloproteinases and their inhibitors in matrix
remodeling’, Trends in Genetics . Elsevier, 6, pp. 121–125. doi:
10.1016/0168-9525(90)90126-Q.
McCall RL, Sirianni RW (2013) ‘PLGA Nanoparticles Formed by Single- or
Double-emulsion with Vitamin E-TPGS’, Journal of Visualized
Experiments , (82), pp. 1–8. doi: 10.3791/51015.
McGrath JC, Lilley E (2015). Implementing guidelines on reporting
research using animals (ARRIVE etc.): new requirements for publication
in BJP. British Journal Pharmacology 172: 3189-3193. doi:
10.1111/bph.12955.
MV, Boland Chang DS, Frazier T, Plyler R, Friedman DS (2014) ‘Electronic
monitoring to assess adherence with once-daily glaucoma medications and
risk factors for nonadherence: The automated dosing reminder study’,JAMA Ophthalmology , 132: 838–844.
http://dx.doi.org/10.1001/jamaophthalmol.2014.856.
Nilsson SFE Drecoll E, Lütjen-Drecoll E, Toris CB, Krauss AH, Kharlamb Aet al. (2006) ‘The prostanoid EP2 receptor agonist butaprost
increases uveoscleral outflow in the cynomolgus monkey’,Investigative Ophthalmology and Visual Science , 47: 4042–4049.
doi: 10.1167/iovs.05-1627.
Ocklind, A. (1998) ‘Effect of latanoprost on the extracellular matrix of
the ciliary muscle. A study on cultured cells and tissue sections.’,Experimental eye research 67: 179–191. doi:
10.1006/exer.1998.0508.
Okeke CO Quigley HA, Jampel HD, Ying GS, Plyler RJ, Jiang Y, Friedman DSet al. (2009) ‘Adherence with Topical Glaucoma Medication
Monitored Electronically. The Travatan Dosing Aid Study’,Ophthalmology 116: 191–199. doi: 10.1016/j.ophtha.2008.09.004.
Overby DR Bertrand J, Tektas OY, Boussommier-Calleja A, Schicht M,
Ethier CR et al. (2014) ‘Ultrastructural changes associated with
dexamethasone-induced ocular hypertension in mice’, Investigative
Ophthalmology and Visual Science , 55(8), pp. 4922–4933. doi:
10.1167/iovs.14-14429.
Pierce KL Gil DW, Woodward DF, Regan JW (1995) ‘Cloning of human
prostanoid receptors.’, Trends in pharmacological sciences .
England, 16(8), pp. 253–256.
Prasanna G, Carreiro S, Anderson S, Gukasyan H, Sartnurak S, Younis H,et al. (2011) ‘Effect of PF-04217329 a prodrug of a selective
prostaglandin EP 2 agonist on intraocular pressure in preclinical models
of glaucoma’, Experimental Eye Research . Elsevier Ltd, 93(3), pp.
256–264. doi: 10.1016/j.exer.2011.02.015.
Raghunathan VK, Morgan JT, Park SA, Weber D, Phinney BS, Murphy CJet al. (2015) ‘Dexamethasone Stiffens Trabecular Meshwork,
Trabecular Meshwork Cells, and Matrix.’, Investigative
ophthalmology & visual science . 56: 4447–4459. doi:
10.1167/iovs.15-16739.
Regan JW, Bailey TJ, Pepperl DJ, Pierce KL, Bogardus AM, Donello JE,et al. (1994) ‘Cloning of a novel human prostaglandin receptor
with characteristics of the pharmacologically defined EP2 subtype.’,Molecular pharmacology , 46: 213–220.
Resnikoff S, Pascolini D, Etya’ale D, Kocur I, Pararajasegaram R,
Pokharel GP, Mariotti SP (2004) Global data on visual impairment in the
year 2002. World Health Organ Bulletin 82: 844-851.Pdf’, 012831(04).
doi: /S0042-96862004001100009.
Saeki T,.Ota T, Aihara M, Araie M et al. (2009) ‘Effects of
prostanoid ep agonists on mouse intraocular pressure’,Investigative Ophthalmology and Visual Science , 50: 2201–2208.
doi: 10.1167/iovs.08-2800.
Sakurai M, Nakamura K, Miura K, Yoshita K, Takamura T, Nagasawa SYet al. (2014) ‘Association between genetic polymorphisms of the
prostaglandin F2α receptor gene, and response to latanoprost in patients
with glaucoma and ocular hypertension’, British Journal of
Ophthalmology , 98(4), pp. 469–473. doi:
10.1136/bjophthalmol-2013-304267.
Sambhara D, Aref AA (2014) ‘Glaucoma management: Relative value and
place in therapy of available drug treatments’, Therapeutic
Advances in Chronic Disease , 5: 30–43. doi: 10.1177/2040622313511286.
Schachtschabel U, Lindsey JD.Weinreb RN (2000) ‘The mechanism of action
of prostaglandins on uveoscleral outflow’, Current Opinion in
Ophthalmology , 11: 112-115.
https://journals.lww.com/co-ophthalmology/Fulltext/2000/04000/The_mechanism_of_action_of_prostaglandins_on.8.aspx.
Scherer WJ (2002) ‘A retrospective review of non-responders to
latanoprost.’Journal of ocular pharmacology and therapeutics 18:
287–291. doi: 10.1089/108076802760116205.
Schneider CA, Rasband WS, Eliceiri KW (2012) ‘NIH Image to ImageJ: 25
years of image analysis’, Nature methods , 9:
671–675.https://www.ncbi.nlm.nih.gov/pubmed/22930834.
Sherwood JM, Reina-Torres E, Bertrand JA, Rowe B, Overby DR (2016)
‘Measurement of Outflow Facility Using iPerfusion.’, PloS one .
United States, 11(3), p. e0150694. doi: 10.1371/journal.pone.0150694.
Shim MS, Kim KY, Ju, WK (2017) ‘Role of cyclic AMP in the eye with
glaucoma’, BMB Reports , 50: 60–70. doi:
10.5483/BMBRep.2017.50.2.200.
Sleath B, Blalock SJ, Covert D, Skinner AC, Muir KW, Robin AL (2012)
‘NIH Public Access’, Opthalmology , 118(12), pp. 2398–2402. doi:
10.1016/j.ophtha.2011.05.013.The.
Stallaert W, Christopoulos A, Bouvier M (2011) ‘Ligand functional
selectivity and quantitative pharmacology at G protein-coupled
receptors’, Expert Opinion on Drug Discovery , 6: 811–825. doi:
10.1517/17460441.2011.586691.
Tamboli V, Mishra GP, Mitra AK (2013) ‘Novel pentablock copolymer
(PLA-PCL-PEG-PCL-PLA)-based nanoparticles for controlled drug delivery:
Effect of copolymer compositions on the crystallinity of copolymers and
in vitro drug release profile from nanoparticles’, Colloid and
Polymer Science , 291: 1235–1245. doi: 10.1007/s00396-012-2854-0.
Tamm ER, Lutjen-Drecoll E (1996) ‘Ciliary body.’, Microscopy
research and technique . 33: 390–439. doi:
10.1002/(SICI)1097-0029(19960401)33:5<390::AID-JEMT2>3.0.CO;2-S.
Wang K, Li G, Read AT, Navarro I, Mitra AK, Stamer WD (2018) ‘The
relationship between outflow resistance and trabecular meshwork
stiffness in mice. Scientific Reports 8:1–12. doi:
10.1038/s41598-018-24165-w.
Wendell SG, Fan H, Zhang C (2020) G protein coupled receptors in asthma
therapy: pharmacology and drug action. Pharmacological Reviews 72: 1-49.
doi: 10.1124/pr.118.016899
WinklerNS, Fautsch MP (2014) ‘Effects of Prostaglandin Analogues on
Aqueous Humor Outflow Pathways’, Journal of Ocular Pharmacology
and Therapeutics , 30: 102–109. doi: 10.1089/jop.2013.0179.
Wold EA, Chen J, Cunningham KA, Zhou J (2019) Allosteric modulation of
class A GPCRs: Targets, Agents, and Emerging Concepts. Journal of
Medicinal Chemistry 62: 88-127. doi: 10.1021/acs.jmedchem.8b00875.
Woodward, DF, Wang JW, Coleman RA, et al. (2019a) ‘A Highly
Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel
Periorbital Delivery Method.’, Journal of ocular pharmacology and
therapeutics 35:265-277.doi: 10.1089/jop.2018.0126.
Woodward DF, Wang J W, Stamer WD, Wang JW, Stamer WD, Lütjen-Drecoll E,
Krauss AH, Toris CB (2019b) ‘Antiglaucoma EP2 Agonists: A Long Road That
Led Somewhere’, Journal of Ocular Pharmacology and Therapeutics35:469-474 doi: 10.1089/jop.2019.0041.
Xu J, Kim GM, Ahmed SH, Xu J , Yan P, Xu XM, Hsu CY (2001)
‘Glucocorticoid receptor-mediated suppression of activator protein-1
activation and matrix metalloproteinase expression after spinal cord
injury.The Journal of neuroscience 21: 92–97.
Zhou J, Patel TR, Sirianni RW, Strohbehn G, Zheng MQ, Duong N, et
al. (2013) ‘Highly penetrative, drug-loaded nanocarriers improve
treatment of glioblastoma’, Proceedings of the National Academy of
Sciences of the United States of America . 110: 11751–11756. doi:
10.1073/pnas.1304504110.